1.2 USP <797> Scope, Core Philosophy & Regulatory Framework

1.2 USP <797> Scope, Core Philosophy & Regulatory Framework

Core Philosophy and the Five Compounding Risks

The governing philosophy of USP Chapter <797> is the proactive, systematic prevention of patient morbidity and mortality. Sterile compounding is not merely a technical mixing exercise; it is an aseptic manufacturing process at an individualized scale that demands absolute assurance of sterility, chemical stability, physical compatibility, and purity. Historical compounding disasters—most notably the 2012 New England Compounding Center (NECC) fungal meningitis outbreak, which CDC tied to 753 cases and 64 deaths in 20 states—demonstrate that compounded sterile preparations manufactured without rigorous environmental controls carry catastrophic potential.

USP <797> specifically targets five critical product-quality and patient-safety risks:

1. Microbial Contamination (Infectious Bioburden): The introduction of viable bacteria (e.g., Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia), fungi (yeasts and molds like Aspergillus or Exserohilum rostratum), or microbial spores into parenteral products. Intravenous or intrathecal administration of a bioburden-contaminated CSP causes rapid bacteremia, fungemia, septic shock, meningitis, and death.
2. Excessive Bacterial Endotoxins (Pyrogenicity): Endotoxins are lipopolysaccharide (LPS) complexes located within the outer membrane of Gram-negative bacteria. Endotoxins are exceptionally heat-stable and easily pass through sterilizing 0.22-micron membrane filters. Even when a terminal autoclave cycle destroys all living bacteria, residual endotoxins remain biologically active. When introduced into systemic circulation or cerebrospinal fluid, endotoxins bind to macrophage CD14 and Toll-like receptor 4 (TLR4), triggering a massive release of pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha). This induces extreme pyrogenic reactions, systemic inflammatory response syndrome (SIRS), hemodynamic collapse, and disseminated intravascular coagulation (DIC).
3. Variability in Intended Strength (Potency Deviations): Mathematical calculation errors, analytical balance miscalibrations, volumetric measuring inaccuracies, or incomplete dissolution yield sub-potent or super-potent preparations. Sub-potency causes critical therapeutic failures (such as breakthrough sepsis from sub-therapeutic vancomycin or accelerated organ rejection from underdosed cyclosporine), whereas super-potency induces acute toxicity (e.g., fatal cardiac arrest from hyperkalemic cardioplegic infusions or catastrophic opioid overdose from concentrated hydromorphone epidurals).
4. Unintended Chemical and Physical Contaminants: Physicochemical incompatibilities generate insoluble precipitates, such as calcium phosphate dibasic crystal formation in neonatal parenteral nutrition. Physical particulate matter—including glass fragments from broken ampules, rubber cores from repeated elastomeric vial stopper coring, plasticizer leachables (such as di-(2-ethylhexyl) phthalate [DEHP] from PVC delivery systems), and environmental dust—causes pulmonary microvascular occlusion, pulmonary granulomas, thrombophlebitis, and foreign-body emboli.
5. Substandard Starting Ingredients: Compounding with bulk active pharmaceutical ingredients (APIs) of uncertain purity, non-compendial grade excipients, expired substances, or components lacking official Certificate of Analysis (CoA) documentation undermines the final preparation's safety profile and therapeutic equivalence.

Scope and Application of USP <797> (2023 Revision)

The current revision of USP <797> was published on November 1, 2022 and became official on November 1, 2023; this guide calls it the 2023 revision. It establishes an unambiguous scope governing the practice environment:

• Target Personnel: Applies to all persons who prepare compounded sterile preparations (CSPs), including pharmacists, pharmacy technicians, pharmacy interns, physicians, nurses, and veterinarians.
• Target Practice Settings: Applies to all locations where CSPs are prepared, including hospital and health-system pharmacies, outpatient infusion pharmacies, ambulatory surgery centers, physician clinics, veterinary compounding units, and university medical laboratories.

Practice Boundaries and Excluded Domains

USP <797> establishes clear regulatory boundaries:

• Medication Administration: USP <797> explicitly governs the preparation, storage, and transport of CSPs. The clinical act of administering a drug to a patient is governed by clinical nursing and medical practice standards, not USP <797>. The one timing link is the immediate-use provision, which requires administration to begin within 4 hours after preparation starts (see 1.4).
• Non-Sterile Compounding: Governed exclusively under USP General Chapter <795>.
• Hazardous Drug Compounding: While the sterility assurance aspects of hazardous sterile compounds fall under USP <797>, all engineering containment, negative-pressure airflow, personal protective equipment (PPE), deactivation, decontamination, and disposal protocols are governed by USP General Chapter <800>.
• Radiopharmaceuticals: The preparation and handling of sterile radioactive drugs are governed exclusively by USP General Chapter <825>, which supersedes USP <797> for radiopharmaceutical compounding.

The Regulatory Triad: Standard Setting vs. Federal vs. State Enforcement

Clinical pharmacy specialists must distinguish between the standard-setting function of the United States Pharmacopeia and the statutory enforcement authority exercised by federal and state regulatory bodies.

Compendial Enforceability Under Federal and State Law

While USP does not inspect or enforce, its standards carry the full weight of federal and state law. Under Section 501(b) of the FD&C Act (21 U.S.C. § 351(b)), a drug recognized in the official United States Pharmacopeia–National Formulary (USP-NF) is legally deemed adulterated if it fails to meet pharmacopeial standards of strength, quality, or purity. Furthermore, state legislatures and State Boards of Pharmacy routinely incorporate USP general chapters directly into their administrative codes. Consequently, a failure to meet USP <797> minimum standards constitutes a violation of both federal adulteration statutes and state pharmacy practice acts.

Traditional Compounding (Section 503A) vs. Outsourcing Facilities (Section 503B)

The passage of the Drug Quality and Security Act (DQSA) in November 2013 formally bifurcated human drug compounding under Title I (the Compounding Quality Act), establishing two legally distinct operational pathways under the FD&C Act:

Section 501(a)(2)(A): Insanitary Conditions Standard

A critical statutory principle tested on the BCSCP examination is that Section 503A exemptions do not shield a pharmacy from federal adulteration enforcement. Under Section 501(a)(2)(A) of the FD&C Act, a drug is deemed adulterated if it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth or rendered injurious to health. The FDA regularly inspects 503A health-system pharmacies following adverse events or state referrals, issuing Form 483 inspection observations for conditions such as:

• Compounding in the presence of unsealed cleanroom ceiling tiles or rusted equipment.
• Exposed operator skin (wrists, neck, forehead) in the ISO Class 5 Direct Compounding Area (DCA).
• Disrupted laminar airflow caused by improper equipment placement inside the Primary Engineering Control (PEC).
• Failure to perform environmental air and surface sampling under dynamic operating conditions.

The Designated Person: Statutory Role & Operational Mandate

A central structural change introduced in the 2023 revision of USP <797> is the formal creation of the Designated Person(s) role. In previous iterations, accountability was vaguely assigned across compounding staff. The 2023 standard mandates that facility leadership officially designate one or more specific individuals who are vested with the authority and accountability for the compounding facility's quality management system.

Core Responsibilities of the Designated Person:

1. Standard Operating Procedure (SOP) Stewardship: Ensuring comprehensive, facility-specific SOPs are developed, formally reviewed at least annually, updated upon operational modifications, and rigorously enforced across all compounding workflows.
2. Personnel Training and Competency Management: Creating and implementing the training program; verifying that compounders and those with direct oversight complete initial qualification, recurring gloved fingertip and thumb sampling (GFT), and media-fill testing; and confirming that restocking and cleaning staff are trained under the facility's SOPs.
3. Facility & Engineering Certification: Overseeing the semiannual (at least every 6 months) certification of all Primary Engineering Controls (PECs) and Secondary Engineering Controls (SECs) by qualified cleanroom certification personnel.
4. Environmental Quality Assurance: Monitoring continuous differential pressure sensors, daily temperature and humidity logs, viable airborne particle counts, and surface microbial sampling data; ensuring an attempt is made to identify recovered microorganisms to the genus level when action levels are exceeded.
5. Out-of-Specification (OOS) Investigations & CAPA: Directing thorough root-cause investigations into sterility failures, endotoxin excursions, media-fill failures, and environmental contamination spikes, and instituting documented Corrective and Preventive Actions (CAPA).
6. Final Release Verification: Ensuring finished CSPs undergo verified physical inspection, labeling confirmation, and release testing prior to clinical distribution.

While the Designated Person may delegate specific operational tasks to qualified team members, the Designated Person retains ultimate regulatory and legal accountability for the facility's compliance with USP <797>.